BioSpace News Archive

The HPC storage solution ensures secure data access coupled with high performance. Since installing WekaFS, SIB supports a growing number of biomedical research projects.

Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced positive topline results from ASCEND MG, a Phase 2a study of IMVT-1401 in patients with myasthenia gravis (MG)

The rate of workforce drug positivity hit a sixteen-year high in 2019, according to a new analysis released today by Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services.

Presentation on Tuesday, September 1 st at 10:20am ET by Nephros, Inc. , today announced that it will be presenting at the LD 500 virtual investor conference on Tuesday, September 1 st at 10:20am ET. Andy Astor, President and Chief Executive Officer of Nephros

Presentation at ECTRIMS/MSVirtual2020 to Inform Analysis of Clinical Outcomes in Ongoing Phase 2 Trial of NurOwn® in Patients with Progressive MS

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personaliz

Technology partnership enables trial sponsors to improve imaging, respiratory, and cardiac safety data quality while reducing patient burden and risk.

Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application covering ALLOCETRA TM , the company’s immunotherapy product candidate. Upon issuance, the new patent will provide added intellectual property protection, including methods, uses and pharmaceutical compositions. The company expects that this new patent will be

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection First in-human study will evaluate the safety and efficacy in acne scars and facial wrinkles Initial data from this study is anticipated in 2021 PITTSBURGH, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), today announced the initiation of the PEARL-1 study, a Phase 1 multi-dose, controlled clinical study of KB301 for the treatment of acne scars and facial